December 6, 2006 – Halozyme gave a license to Roche to use its proprietary drug delivery technology, a deal that could be worth up to $600 million; Wyeth released data showing that bifeprunox maintained stability in schizophrenia patients; Avigen reported AV650 was well tolerated and safe in patients who suffer from spasticity and spasm; ArQule began administering cancer drug ARQ 171, Novartis presented 12 Galvus abstracts at a diabetes conference; and Indevus will out-license aminocandin to Novexel, a spin-off from Sanofi-Aventis. More details...
